Two recent clinical review articles (see below) indicate that most adults with inflammatory bowel disease (IBD) admitted to the hospital would benefit from venous thromboembolism (VTE) prophylaxis. Since children with IBD have a lower risk of VTE, it is unclear whether more efforts at VTE prophylaxis are needed in the pediatric population. Previous studies have shown that in those IBD patients less than 20 years, the incidence rate was 8.9 per 10,000 person years. In contrast, in those IBD patients older than 60, the incidence rate was 54.6 per 10,000 person years (VTE with IBD | gutsandgrowth).
- Inflammatory Bowel Dis 2015; 21: 1195-1203.
- Inflammatory Bowel Dis 2015; 21: 1204-1213.
In the first article, the authors review common risk factors and disease-specific risk factors. They state the following:
Because hospitalization puts the patient at greater risk for TE compared with an outpatient setting, all hospitalized patients should receive anticoagulant therapy in the absence of severe bleeding, even if the patients are in remission.
The second review describes epidemiological data, pathophysiology, and VTE prevention. They also state the following:
Currently, the most effective strategy for preventing VTE in hospitalized patients with IBD with active disease is prophylactic anticoagulation. In fact, all of the current guidelines for the management of patients with IBD suggest the use of anticoagulants to prevent VTE.
The authors note that the rates of thromboprophylaxis are “still unacceptably low.”
Bottomline: In adults with active IBD, VTE prophylaxis is recommended. In the pediatric population due to the lower incidence of VTE, more study is needed –perhaps another project for ImproveCareNow.
Cochrane Review of Vedolizumab for Ulcerative Colitis. Inflammatory Bowel Dis 2015; 21: 1151-59. Based on four studies (n=606 patients) with low risk of bias, pooled analysis showed that vedolizumab was superior to placebo for induction of remission (RR=0.86), clinical response (RR=0.82), endoscopic remission (RR=0.82) and for achieving remission at 52 weeks in week 6 responders (RR=2.73). No statistically significant difference was observed in the incidence of adverse events between vedolizumab and placebo.